What’s next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care
GLP-1 innovation is reshaping modern medicine, from new drug designs and expanded indications to smarter manufacturing, coverage, and digital integration.
At a glance
Read on to get our full commentary, or use the links below to jump to a specific area of interest:
Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s). Originally developed for diabetes management, these drugs, popularized under brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound, are redefining how we think about obesity, metabolic health, and even chronic disease prevention. And increasingly, GLP-1s are no longer just about controlling blood sugar. They have become cultural touchstones, economic disruptors—and, as we’ll discuss today, the centerpiece of a high-stakes race to innovate among pharmaceutical giants, biotech innovators, payers, and digital health platforms. In this post, we’ll go deep on that race to innovate and its implications. There’s a lot to unpack, so we’ve structured our thoughts into three distinct sections:
- We’ll start by sharing our key insights and predictions about where the innovation race is heading—and what it means for the industry
- From there, we’ll overview what the race has looked to date (including key differentiators between major competitors Eli Lilly and Novo Nordisk)
- Finally, we’ll go deep on the five vectors of innovation that will define the innovation race moving forward:
- Drug design and formulation
- Expanded indications
- Manufacturing and supply chain
- Digital integration and adherence
- Cost and coverage
GLP-1 innovation: Key insights and predictions
Union Healthcare Insight
Log in to continue reading
Not a member yet? Create a free account for limited access.
Related insights
The Great Utilization Shift
Healthcare’s next forced efficiency leap is AI. Where does your organization stand?
The health-system utilization forecasting conundrum: One size definitely doesn’t fit all.